“KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s712. Accessed April 21, 2026. https://skin.dermsquared.com/skin/article/view/3898.